R
Richard M. Weinshilboum
Researcher at Mayo Clinic
Publications - 571
Citations - 33641
Richard M. Weinshilboum is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacogenetics & Thiopurine methyltransferase. The author has an hindex of 86, co-authored 529 publications receiving 31166 citations. Previous affiliations of Richard M. Weinshilboum include University of Rochester & Royal Hallamshire Hospital.
Papers
More filters
Journal Article
Mouse liver thiol methyltransferase. Assay conditions, biochemical properties, and strain variation.
TL;DR: Since the properties of TMT in mouse liver are similar to those of the enzyme in human tissue, the inbred mouse will be a useful experimental animal model in which to study the regulation and function of T MT.
Journal ArticleDOI
Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?
Journal ArticleDOI
Dopamine-β-hydroxylase activity in serum
TL;DR: This chapter describes the dopamines- β -hydroxylase (DBH) activity in serum, which is biochemically similar to DBH activity in the adrenal medulla and sympathetic nerves with regard to co-factor requirements, requirement for oxygen; Michaelis–Menten constant for substrate, and response to the addition of cupric ion to inhibit endogenous inhibitors of the enzyme.
Journal Article
Human thiopurine methyltransferase
Ronald Honchel,Ibrahim A. Aksoy,Carol L. Szumlanski,Thomas C. Wood,Diane M. Otterness,Eric D. Wieben,Richard M. Weinshilboum +6 more
Journal ArticleDOI
Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.
Sisi Qin,Andy R. Eugene,Duan Liu,Lingxin Zhang,Drew Neavin,Joanna M. Biernacka,Jia Yu,Richard M. Weinshilboum,Liewei Wang +8 more
TL;DR: Dual roles for TSPYLs in mediating serotonin transport and the metabolism of selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder are observed and genetic variation in TSPyl genes may be novel indicators for baseline severity of depression and SSRI poor response.